Healthcare Industry News: Siemens Healthcare
News Release - May 27, 2010
Calypso Medical's Real-Time Tumor Tracking Technology Improving Prostate Cancer CareCalypso specialists will provide Beacon® transponder implant training at AUA
SEATTLE--(HSMN NewsFeed)--Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced that it will exhibit at the American Urological Association’s Annual Meeting (AUA), taking place from May 29 to June 3 at the Moscone Center in San Francisco. During the meeting, Calypso will provide onsite physician implant training for its miniature Beacon® electromagnetic transponders at booth #4017. These transponders are the core of the Calypso® System, which has been shown to help reduce radiation-related side effects. More than 6,000 patients have already benefited from this cutting-edge prostate cancer care technology.
The Calypso System, with its GPS for the Body® technology, utilizes implanted Beacon transponders to provide precise, continuous information on the location of the tumor during external beam radiation therapy. Any movement by the patient, including internal movement of the tumor, may cause the radiation to miss its intended target and hit adjacent healthy tissue. The real-time position information provided by the Calypso System allows physicians to deliver maximum radiation directly to the tumor while sparing the surrounding healthy tissues and organs from exposure. In contrast to other guidance techniques, Calypso’s electromagnetic technology is the only non-ionizing guidance solution to keep the treatment precisely focused on the prostate or post-operative prostatic bed without adding unnecessary radiation. Currently the Calypso System is cleared by the U.S. Food & Drug Administration (FDA) for use in radiation therapy for the prostate and prostatic bed; however, the technology is designed for body-wide applications.
“For prostate cancer patients who make the decision to undergo radiation therapy, the Calypso System allows physicians to deliver the highest level of patient care,” said Dr. C. Garo Gholdoian of Urology Nevada in Reno, Nevada. “By implanting Beacon transponders, I’m helping to ensure that radiation is delivered more accurately to the tumor and that surrounding healthy tissue is spared.”
A clinical study entitled, “Assessing the Impact of Margin Reduction (AIM),” published in the May issue of Urology, demonstrated that prostate tumor tracking utilizing the Calypso® System during high-dose intensity-modulated radiotherapy (IMRT) allowed physicians to deliver a higher dose of radiation with smaller planning treatment volume (PTV) margins, while reducing treatment-related side effects.
“Calypso is a technological advance that allows us to get better treatment outcomes and to give a better result with less toxicity,” said Dr. Richard Harris of UroPartners in Glenview, Ill. “Quality of care is of the utmost importance and whatever technologies we can embrace to help bring about that quality of care is something exciting for us and good for our patients.”
About Calypso Medical
Calypso Medical Technologies, Inc. is a Seattle-based, privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Healthcare, Elekta Corporation and Philips Medical. Additional information can be found at www.calypsomedical.com.
Source: Calypso Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.